当前位置: X-MOL 学术Pract. Neurol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Patent foramen ovale
Practical Neurology ( IF 2.4 ) Pub Date : 2020-04-16 , DOI: 10.1136/practneurol-2019-002450
Vafa Alakbarzade 1 , Tracey Keteepe-Arachi 2 , Nazia Karsan 2 , Robin Ray 2 , Anthony C Pereira 2
Affiliation  

Patent foramen ovale (PFO) is the most common anatomical cause of an interatrial shunt. It is usually asymptomatic but may cause paradoxical embolism, manifesting as stroke, myocardial infarction or visceral/peripheral ischaemia. PFO is a risk factor for stroke and may be associated with migraine with aura. New evidence suggests PFO closure reduces the risk of recurrent ischaemic stroke in a highly selected population of stroke survivors: those aged 60 years or younger with a cryptogenic stroke syndrome, a large right-to-left shunt, an atrial septal aneurysm and no evidence of atrial fibrillation. They benefit from percutaneous PFO closure in addition to antiplatelet therapy, rather than antiplatelet therapy alone. Current evidence does not support PFO closure in the treatment of migraine.

中文翻译:

卵圆孔未闭

卵圆孔未闭 (PFO) 是房内分流最常见的解剖学原因。它通常无症状,但可能引起反常栓塞,表现为中风、心肌梗塞或内脏/外周缺血。PFO 是中风的危险因素,可能与先兆偏头痛有关。新证据表明,PFO 封堵可降低经过高度筛选的卒中幸存者的复发性缺血性卒中风险:年龄在 60 岁或以下且患有隐源性卒中综合征、大的右向左分流、房间隔动脉瘤且没有证据表明心房颤动。除了抗血小板治疗外,他们还受益于经皮 PFO 封堵,而不是单独的抗血小板治疗。目前的证据不支持 PFO 封堵治疗偏头痛。
更新日期:2020-04-16
down
wechat
bug